Skip to content

Menu

About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
- Management
- Clinical Advisors
- News
- Media
- Articles
Contact
International

July 11 2017

LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

View the article.

Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia LimFlow Announces Publication of Positive Results from Pilot Study of LimFlow Percutaneous Deep Vein Arterialization (pDVA) System

Related Posts

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT

LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

Recent Posts

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING
US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT
LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA
THE LIMFLOW SYSTEM FOUND TO BE COST-EFFECTIVE, ACCORDING TO THE NEWEST STUDY PUBLISHED IN THE JOURNAL OF CRITICAL LIMB ISCHEMIA
PUBLICATION OF ONE YEAR OUTCOMES FROM PROMISE I U.S. STUDY OF THE LIMFLOW SYSTEM DEMONSTRATES EXCELLENT SUSTAINED AMPUTATION-FREE SURVIVAL AND WOUND HEALING IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

LimFlow, Inc.
3031 Tisch Way
110 Plaza West
San Jose, CA 95128
United States of America

info@limflow.com
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.

©2022 LimFlow SA | Site designed by The Deciding Factor, Inc.